Clarendon Fund Managers

🌿 The Present Tree - £1.8m deal announcement 🌿 I'm very pleased to share the completion of a £1.8m investment into The Present Tree, a sustainable luxury gifting brand primed to pursue its growth plans and anchor itself as a dominant player in the luxury garden gifting market. The Present Tree has built a premium, purpose-led brand with demonstrable traction, underpinned by disciplined founder-led execution, a strong team, and a clear commitment to sustainable operations. This £1.8m investment is a step change, providing the capacity to scale the business while maintaining the quality and values that underpins their offering. We are excited to be backing Catherine and the team for the next phase of growth, and we see a clear pathway for the business to become a category-defining sustainable luxury gifting brand. Excited to see what the journey holds for Catherine Cunningham and her excellent team! Clarendon Fund Managers British Business Bank British Business Bank Northern Ireland Neil Simms Brian Cummings Sian Mclaughlin Sue Barnard Mark Sterritt https://lnkd.in/eeVTSRNN #venture #seed #seriesa #founder #consumerproduct #scale #D2C

News | Co-Fund III has invested over £3m in 13 local companies in its first year  Alongside £5.4m of private investment and £1.9m of leveraged funding, Co-Fund NI III has helped unlock over £10m of investment for local SMEs.  🤝 We’re proud to have supported this fantastic milestone through our Access to Finance initiative.  💰 Building on our long-term commitment to supporting business growth, Co-Fund III is managed by Clarendon Fund Managers  and provides a £39 million equity investment fund that helps ambitious companies grow with confidence.  💡 From supporting female-founded companies like Senergy Innovations Ltd to helping develop new ideas in health sciences, fintech and clean energy, Co-Fund III is already making a real impact.  Here’s to continued momentum, and many more success stories for Northern Ireland’s entrepreneurs!  Kieran Donoghue | Kathryn Hill | Department for the Economy NI | Steven Scullion | NI Chamber | CBI Northern Ireland | FSB Northern Ireland (Federation of Small Businesses) | Lisburn & Castlereagh City Council

📣 Sonas Pharma Announces Pre‑Seed Investment Round Backed by SFC Capital and Clarendon Fund Managers Sonas Pharma, a biotechnology company developing next‑generation therapeutics for obesity and epilepsy, is delighted to announce the successful closing of its pre‑seed investment round, led by SFC Capital with participation from Clarendon Fund Managers. This funding marks an important milestone in Sonas Pharma’s mission to build safer, mechanism‑driven endocannabinoid system based therapeutics, leveraging modern insights in GPCR pharmacology, peripheral restriction, and rational drug design. 🚀 A Strong Vote of Confidence in Sonas Pharma’s Scientific Strategy The investment will accelerate: Advancement of Sonas’s CB1‑targeting metabolic program, built on neutral, peripherally‑restricted pharmacology Continued development of the company’s epilepsy drug discovery platform Expansion of core R&D capabilities and early‑stage translational infrastructure Recruitment of key scientific and operational talent 💬 CEO Comment Chris Hayes, CEO & Co‑Founder of Sonas Pharma, commented: “We’re thrilled to have the backing of SFC Capital and Clarendon Fund Managers as we build a new generation of endocannabinoid system therapeutics. Their support validates our mechanism‑first strategy and allows us to advance programs designed to deliver real clinical impact in two areas of huge unmet medical need in epilepsy and obesity.” 💬 Investor Statements SFC Capital: “Sonas Pharma stands out with its rigorous scientific foundation and clear strategy for addressing major unmet needs in metabolic and neurological disease. We’re excited to support their growth at this early stage.” Adam Beveridge, Principal SFC Capital Clarendon Fund Managers: “We are delighted to invest in Sonas through the Invest NI-backed Co-Fund and to support the company as it progresses towards important development milestones. Sonas has the foundations to build a best-in-class drug discovery company from Northern Ireland. This investment reflects our continued commitment to supporting ambitious local businesses with global reach.”   🌿 About Sonas Pharma Sonas Pharma is a preclinical biotechnology company focused on developing best-in-class, next‑generation endocannabinoid system modulators for high‑burden metabolic and neurological disorders. By combining validated human biology with precision pharmacology, Sonas aims to bring forward differentiated small molecules designed to be both effective and safe.   About Co-Fund III Co-Fund III invests alongside private investors on a wholly commercial basis. The £39m fund expects to leverage over £60m from the private sector, opening up more than £100m of investment for Northern Ireland SMEs. Since the first Co-Fund was established in 2011, the fund’s investment of £54m has leveraged over £335m from private and public investors into 109 companies, enabling them to create and maintain over 1,600 local jobs and sell their products around the world.

TeamFeePay secures new investment to fuel UK & European Growth! We’re delighted to announce that TeamFeePay has secured new investment, enabling us to accelerate growth across the UK, expand into Europe and create 75 new jobs over the next two years. A huge thank you to YFM Equity Partners, Clarendon Fund Managers, Techstart Ventures and our Angel Investors for backing our next phase of growth. We would like to also thank our clubs, players, parents, admins and club volunteers for your ongoing support - this next chapter wouldn’t be possible without you. Exciting times ahead for grassroots sport ⚽ Read the full article here: https://loom.ly/6NEQmMw #TeamFeePay #SportsTech #GrassrootsSport #UKTech #EuropeanExpansion #StartupGrowth